Amanta Healthcare Ltd
Amanta Healthcare Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #82 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Amanta Healthcare Ltd Q4 FY26 key numbers
- Revenue
- SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28.
As stated in Amanta Healthcare Ltd's Q4 FY26 earnings call transcript · published 24 May 2026. Reported figures, not investment advice.
The short version
SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28. FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost.
From Amanta Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28.
- New product pipeline of 20 products in inhalation and ophthalmic segments to commercialize in FY27-28, supporting growth.
- Export revenue grew from 32% in FY25 to 39% in FY26; active marketing in 25-30 countries with key markets including UK, Thailand, Philippines, South Sudan.
- Export markets like East Africa show cyclical buying patterns; export sales generally stronger in H2.
- Domestic IV fluid demand growing at 8-10% year-on-year, with two-port systems growing faster at 12-13%.
- Capacity ramp-up expected to reach full utilization within 3-4 months post commissioning, driving scale and margin expansion.
2 more points from Amanta Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amanta Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- SteriPort expansion: Commissioning expected by June 2026, aiming for operational by June 20; will add approx. INR110-120 crore top line from FY27 onwards with EBITDA margin around 27%.
- SVP (Small Volume Parenteral) line: To be commissioned in late 2026 (October-December), focusing on inhalation and ophthalmic product pipelines, expected commercialization in FY27-28.
- Solar power project: 10.8 MW captive solar plant to be commissioned by May 2026, expected to reduce power costs by about INR75 lakh per month starting FY27, improving cost efficiency and ESG profile.
2 more points from Amanta Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amanta Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Amanta Healthcare Limited does not maintain a long-term order book extending over one year.
- Export orders are rolling and cyclic, with visibility of around 3 to 6 months in some markets.
- For example, the East African market's significant purchases happen from September to March, and export numbers tend to be better in H2 than H1.
2 more points from Amanta Healthcare Ltd's call on order book
Create a free account to keep reading this call
Amanta Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amanta Healthcare Ltd's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amanta Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amanta Healthcare Ltd Q4 FY26 results?
SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28. FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost.
What is Amanta Healthcare Ltd share price analysis?
Amanta Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amanta Healthcare Ltd planning capital expenditure?
SteriPort expansion: Commissioning expected by June 2026, aiming for operational by June 20; will add approx.
Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.